DaVita Inc. (DVA) Earnings Call Transcript & Summary

October 29, 2025

New York Stock Exchange US Health Care Health Care Providers and Services earnings 43 min

What were the key takeaways from DaVita Inc.'s October 29, 2025 earnings call?

In the third quarter of fiscal year 2025, DaVita Inc. reported adjusted operating income of $517 million and adjusted earnings per share (EPS) of $2.51, which were consistent with internal expectations but fell short of consensus estimates. The company reaffirmed its full-year guidance for adjusted operating income between $2.035 billion and $2.135 billion and adjusted EPS of $10.35 to $11.15, while narrowing the ranges. Management highlighted challenges such as a 1.5% year-over-year decline in U.S. treatment volume, impacted by external factors including a severe flu season and a cyber incident, which could influence future performance.

What topics did DaVita Inc. cover?

  • Volume Decline: DaVita experienced a 1.5% year-over-year decline in U.S. treatments per day, attributed to 'higher mortality from a severe flu season' and 'lost admissions opportunities as the result of Hurricane Helene and the cyber incident.' Management expects this trend to improve in 2026 as these headwinds are not expected to recur.
  • Guidance Reaffirmation: Management reaffirmed the midpoint of its full-year guidance for adjusted operating income at $2.85 billion and adjusted EPS at $10.75, while narrowing the ranges. They noted that 'we remain on track to achieve our full year goals.'
  • Investment in Technology: DaVita is investing in technology infrastructure, including a new clinical platform and AI solutions, which management believes are 'critical to advancing clinical care' despite leading to higher G&A growth in the short term.
  • Payer Mix Concerns: Management highlighted potential volatility in payer mix due to ongoing policy debates, stating that 'we're among the many who are closely monitoring the impact of enhanced premium tax credits on commercial mix.' This uncertainty could significantly impact revenue.
  • Free Cash Flow Generation: DaVita generated free cash flow of $604 million in the quarter, which supports its capital allocation strategy, including share repurchases. The company repurchased approximately 10 million shares year-to-date.

What were DaVita Inc.'s October 29, 2025 results?

  • Adjusted Operating Income: $517 million (vs consensus of $570 million, miss by $50 million)
  • Adjusted EPS: $2.51 (vs consensus of $2.63, miss by $0.12)
  • Free Cash Flow: $604 million (strong cash generation supporting capital allocation strategy)
  • U.S. Treatment Volume Change: -1.5% (year-over-year decline due to external factors)
  • Full Year Adjusted Operating Income Guidance: $2.035 billion to $2.135 billion (reaffirmed midpoint guidance)
  • Full Year Adjusted EPS Guidance: $10.35 to $11.15 (reaffirmed midpoint guidance)

DaVita's Q3 results indicate challenges ahead, particularly with treatment volume and payer mix volatility. However, the reaffirmation of guidance and strong cash flow generation provide a buffer. Investors should monitor the impact of external factors on volume and the company's ongoing investments in technology and clinical research as potential catalysts for future growth.

Earnings Call Speaker Segments

Nic Eliason

executive
#1

Thanks for joining us for this third quarter conference call, and we're glad you continue to follow our company. This is Nic Eliason speaking, and I serve as Group Vice President of Investor Relations. With me on the call are Javier Rodriguez, who is our CEO, and Joel Ackerman, our CFO. I want to point out that we might make forward-looking statements on this call as defined under the federal securities laws. Known and unknown risks and uncertainties apply to each of these statements, and those factors could lead to actual results differing materially from what the forward-looking statements describe. If you want more information about these risks and uncertainties, please look at our third quarter earnings press release along with our SEC filings, which include our latest annual report on Form 10-K, every quarterly report on Form 10-Q filed afterward, and any other filings we subsequently submit to the SEC. The information we have right now forms the basis for our forward-looking statements, and we have no intention and take on no obligation to revise those statements, unless the law demands it. We also want to remind everyone that some non-GAAP financial measures will be covered on this call. You can find a reconciliation of those non-GAAP measures against the closest comparable GAAP financial measures in our earnings press release, which was furnished to the SEC and is posted on our website. At this point, I'll hand things over to Javier Rodriguez.

Javier Rodriguez

executive
#2

Thank you, Nic. Good afternoon, everyone, and thanks for being with us on today's call; operating within a shifting health care landscape is something we're used to, and today fits that pattern. We're now at day 29 of the government shutdown, and important health care policy choices are still unsettled. Although these events carry genuine consequences, our attention stays on the thing that matters most, delivering outstanding care; that emphasis serves our patients' interests and also keeps producing steady financial outcomes. Results for our third quarter matched what we had anticipated and keep us positioned to hit our guidance for the entire year. On top of that, these results let us keep investing to better patients' lives and improve how our teammates and physicians experience their work. Later today, I'll cover the key points from our third quarter results, refresh our full year guidance and go over several swing factors for 2026; but before anything else, as we always do, we'll start with clinical highlights. Today's focus will be our research organization, which goes by DaVita Clinical Research, or DCR. Backed by a committed group of medical directors and data scientists, indeed, by one of the biggest sources of patient data anywhere in the country, DCR has played a key role in pushing kidney care research forward. Here are a few figures that show just how much this team has contributed. DCR runs over 250 research sites across the United States and has carried out over 500 clinical trials. This group of researchers has helped secure FDA approval for dozens of ESKD drugs, and DCR research and data has supported over 700 clinical publications; driven by innovation and patient safety, DCR has contributed to developing new therapies, bettering outcomes and creating value for patients and physicians throughout the kidney care community; this enduring dedication highlights our standing as a leader in clinical research. Most recently, DCR is assessing outcomes of middle molecule clearance with middle cut-off dialyzers, which will deliver critical data specific to the U.S. and could mark a meaningful step forward in improving patient outcomes. That's merely the newest illustration of how DaVita is furthering the development of new therapies and actively shaping kidney care's future. Turning now to our financial results; we posted third quarter adjusted operating income of $517 million and adjusted earnings per share of $2.51. These results aligned with our internal expectations. Joel will walk through the quarter in detail, but at a high level, we keep managing patient care costs effectively even as U.S. treatment volume declined roughly 1.5% year-over-year. Before I get into full year guidance, let me offer some detail on one of our ongoing strategic priorities: investing in technology infrastructure. As a reminder, last year, we finished rolling out our next-generation clinical platform. We keep improving that system and are making other long-term investments to replace our scheduling system and further upgrade our revenue operations technology. At the same time, we're bringing AI solutions into use across our platform. This covers use cases we build in-house, chances tied to applications that can succeed commercially, and partnerships with outside vendors. Although these initiatives lead to greater G&A expansion, we see these outlays as essential for moving clinical care forward, bettering how both our patients and teammates experience things, and generating cost efficiencies over the long run. I'll shift now to the outlook for the entire year. We're holding to the midpoint of our guidance ranges for adjusted operating income and adjusted earnings per share, though we are tightening both ranges. Our updated expectation for the full year is adjusted operating income of $2.035 billion to $2.135 billion, with adjusted earnings per share between $10.35 and $11.15. I know plenty of you have your sights set on 2026 already. It's too soon to give formal guidance, but let me go through a few important variables that will shape how we see next year. The first is volume; in 2025 we ran into multiple headwinds that we don't anticipate happening again, such as Hurricane Helene, a tough flu season, and the cyber incident. Past those one-off events, and as I mentioned during the prior quarter, we'll keep pushing our efforts to make clinical headway on lowering mortality and fueling treatment growth. The second is payer mix, which is currently the subject of active policy debate. Like many others, we are watching closely how enhanced premium tax credits affect commercial mix; we will likewise evaluate the continuing recalibration of the Medicare Advantage landscape, since shifting market dynamics stemming from government policy and payer behavior influence Medicare Advantage enrollment and insurance mix. The third is Integrated Kidney Care, or IKC. We're waiting for the government's CKCC program to release final results for the 2024 performance year. When that release happens and when the related operating income gets recognized could move between 2025 and 2026. We're pleased with our 2025 progress, and it's a key reminder that the timing of operating income stays hard to forecast. In short, a variety of possible outcomes remain for 2026, and we expect to gain more clarity on each of these factors in the months ahead; and as usual, we'll give formal guidance on our fourth quarter earnings call in February. To close out my remarks, we're still on track to hit our full year objectives. At the same time, our long-term spending on IT and clinical innovation bolsters our capacity to provide outstanding patient care and build lasting value. As we head toward 2026, we're tracking numerous variables that will define the year ahead, and we're confident in our ability to steer through them successfully. I'll hand things over now to Joel, who will go deeper into our financial performance.

Joel Ackerman

executive
#3

Thank you, Javier. For the third quarter, adjusted operating income came in at $517 million, adjusted earnings per share reached $2.51, and free cash flow totaled $604 million. I'll walk through the individual pieces of our results, starting with U.S. dialysis. First, treatment volume. Compared with the third quarter of 2024, U.S. treatments per day fell 1.5%, which matched what we had anticipated. Two factors are mainly behind that decline: first, the mix of days, since this quarter leaned a bit more toward Tuesdays, Thursdays and Saturdays than Q3 of last year did. Second, census trends weighed negatively, driven by higher mortality from a severe flu season along with lost admissions opportunities stemming from Hurricane Helene and the cyber incident. Moving on to what we earned per treatment: that figure climbed by about $6 from the second quarter. Most of the lift came from rate increases and stronger phosphate binder revenue, plus the fact that the cyber incident dragged down Q2 RPT. Working against those gains were a modest shift in payer mix and the usual quarter-to-quarter noise. We still expect full-year RPT growth to come in at the low end of the 4.5% to 5.5% range we originally guided. Reaching that means Q4 needs to pick up speed, and we look for that from vaccines, customary rate increases, and an unusually large benefit from settling older claim balances. Switching to patient care costs: PCCs per treatment were up about $5 quarter over quarter. Wage growth of the usual kind drove most of that shift, and we also saw more spent on pharmaceuticals because we dispensed a larger volume of phosphate binders than we did in Q2. If you take away what phosphate binders contributed, patient care costs are still coming in above the targets we set at the start of the year. We continue to expect PCCs per treatment for the full year to be 5% to 6% higher than in 2024. Adjusted operating income internationally came to $27 million, which is $9 million lower than the second quarter, largely due to the one-time gain we highlighted three months ago. Over in IKC, our value-based care segment, the adjusted operating loss for Q3 was $21 million. Like I've said before, it's tough to predict how IKC will fall out quarter by quarter. Even so, we're confident that IKC's adjusted operating results for 2025 will come in flat or better than what we saw last year, which lines up with what we told you at the start of the year. Overall, our third quarter operating results matched what we were looking for. Taking the middle of our narrowed adjusted operating income range, the guidance it implies for the fourth quarter works out to a sequential rise of roughly $60 million. For the fourth quarter, we anticipate the main factor behind the improvement will be more treatments being performed, which stems from a healthier mix of treatment days, along with revenue per treatment rising sequentially and the timing of IKC revenue. Those gains should be partly offset by the usual seasonal uptick in patient care costs and G&A. Now turning to how we allocate capital: in Q3 we bought back 3.3 million shares, and since the quarter closed we've repurchased another 400,000 shares. Year to date, as of today's earnings call, we've bought back approximately 10 million shares, totaling roughly $1.5 billion. As a reminder, the 400,000 shares acquired in October were done through the repurchase agreement we've publicly filed with Berkshire Hathaway. So according to what we agreed to, just ahead of each earnings call for DaVita, we buy enough shares from Berkshire to restore its ownership position to 45%. That transaction follows a set formula set out in the contract. When the quarter ended, our leverage stood at 3.37x consolidated EBITDA, which falls within the 3 to 3.5x range we target. Now looking at the remainder of 2025, as Javier mentioned, we're confirming our guidance for full year adjusted operating income, with a midpoint of $2.85 billion, along with adjusted earnings per share, with a midpoint of $10.75, and we're tightening the band on both of those ranges. We're eager to share our full year results and give 2026 guidance the next time we speak, which will be in February; that wraps up my prepared remarks for today. Operator, could you please open the call for Q&A.

Kevin Fischbeck

analyst
#4

Great. A few points stood out in what you said ahead of the Q&A. First, you brought up the volume figure for the coming year. I get the one-off items you called attention to this year. Excluding those 3 — actually it was 4 items that you — or 3 items you named, the hurricane, the cyber and flu — how do you figure volumes would have shaken out this year? What would that figure be?

Joel Ackerman

executive
#5

Yes, Kevin, I'll handle that one. My guess is it's roughly a 75 to 100 basis point headwind on '25 volume from those 3 things combined, and that's a mix of census and missed treatment rate.

Kevin Fischbeck

analyst
#6

Kevin, one more item in our volumes stood out to us: you brought up efforts to bring mortality down. Can you share anything further there? My guess is that this isn't the kind of thing that appears within a single quarter, though perhaps there's some hope it could get better in the coming year? Or does it instead come gradually and consistently across time?

Javier Rodriguez

executive
#7

Yes, Kevin, exactly as you described it, it comes gradually across time. Every one of our clinical protocols is under review — time on therapy, fluid, other protocols, GLP-1s and other medications — so we can figure out the optimal approach for tackling this, since bringing our mortality down is truly necessary. Naturally, at some point we'll discuss mid-molecule clearance, and — but returning to what you raised, that requires time.

Kevin Fischbeck

analyst
#8

All right. And the final thing I wanted to ask about. Regarding that MA enrollment item, it seems to be a larger swing factor for 2026 than I'd anticipated. I realize there's a lot of movement there. When you refer to a swing factor, do you mean simply changes in membership among payers — that is, your rates with various payers differ enough to shift the needle materially? Or does your concern lie with broad declines in MA enrollment, with people going back to traditional Medicare or Medicare plus supplemental?

Javier Rodriguez

executive
#9

Ultimately, you pointed to 2 variables, and that's mix — and inside that mix, revenue differs by payer. We take no position on it since we can't predict the direction. Conversely, enrollment does vary, and you're hearing many payers discuss volatility in their enrollment. So we're merely pointing out that we lack any specific insight; instead, the marketplace feels more dynamic right now.

Kevin Fischbeck

analyst
#10

All right. Yet that's a possible shift large enough that you decided it warranted mentioning? I suppose personally, I wouldn't view it as such a major variable, though it clearly is one.

Javier Rodriguez

executive
#11

Naturally, how much it matters depends on who's judging. Still, when all is said and done, with so much going on and so many members involved, a situation could arise in which things move either way; therefore we chose to flag it. I mean, if next year's revenue per treatment were the topic, that element would be present. Beyond that, naturally, comes open enrollment, which involves the matter of tax premium credits currently under discussion with the federal government; as a result, those 2 things are somewhat less settled at this moment than they would be in typical years.

Joel Ackerman

executive
#12

Even so, Kevin, I believe — Javier makes a good point, and I'm with him; our aim is to point out places where variability could arise. Still, I'd say it's fair to state that when it comes to financial swings, commercial mix matters more than MA mix.

Andrew Mok

analyst
#13

Thanks for all the detail regarding 2026. Perhaps returning to the volume question. You mentioned the 75 to 100 basis points of one-time items that won't happen again next year. So, I suppose, is it reasonable to view that as a sensible baseline when we consider possible growth for next year? And Javier, I believe you mentioned spending on technology, infrastructure, scheduling systems. Should any of those be expected to significantly affect treatment growth? Or is there anything else within your control that could impact the volume situation?

Joel Ackerman

executive
#14

Yes, Andrew, I'll handle the first part; so if you were to convert that 75 to 100 bps from '24 to '25, I think '26 over '25, again, if you're looking at year-over-year growth rates, you're probably seeing a 50 to 75 basis point structural gain in '26 growth compared to '25 growth. And that stems mostly from the flu and the cyber incident. The hurricane is essentially annualizing out and is offset the — essentially the advantages of that are offset by the reality that there's a minor headwind in '26 over '25 from day mix. Just to remind you, '25 over '24 had a 20 basis point day mix headwind; and then '26 over '25 has an extra 10 basis point headwind. '27 will be a tailwind.

Javier Rodriguez

executive
#15

So once you've worked through all of those figures and brought everything together — after running all of those calculations and settling the total, if you take 2025 as your starting point, a year for which our guidance calls for a decline in volume of 75 to 100 basis points, then honestly, based on where things stand for me right now, it appears we'll land nearer to 100 basis points. The missed treatment rate is genuinely what's driving that; so for 2025 growth, let me work with negative 100 basis points as the figure. Structurally speaking, you'd want to make an adjustment there to account for all the other dynamics. So I'm not offering guidance at this point — what I'm doing is simply trying to connect the dots on how to think about where you begin when constructing '26. From that negative 100 basis points in '25, you'd see an improvement of 50 to 75. That leaves you starting from an adjusted growth figure in '25 of negative 25 to negative 50, which becomes the base for building a '26 number.

Andrew Mok

analyst
#16

Understood. Is there anything you'd like to say about...

Javier Rodriguez

executive
#17

Andrew, regarding what you asked next, a great many things are getting investment from us. In the U.S. in particular, volume will be affected. What we can say in brief is that we have no specific knowledge of volume, but expanding your question to the P&L, my answer would be that optimism is warranted, and hard work is underway. Volume could be moved by some of the models currently in development on our end. Take one instance: something is being built by us that would risk stratify hospitalization. Should an intervention be possible, and should it alter hospitalization, then volume would naturally be affected. Conversely, models are being developed by us targeting the cost structure — for instance, administrative matters within the call centers and revenue operations capable of handling authorizations far more swiftly and with greater reliability, which would in all likelihood yield a higher collection. So those represent a few illustrations of what I called out at the opening.

Andrew Mok

analyst
#18

Thanks; and regarding the premium tax credits, I believe the most recent projection you provided for that headwind was $120 million across 3 years. Is that figure still appropriate to use? Also, could you speak to how your exchange growth has gone and its trajectory over the course of the year?

Javier Rodriguez

executive
#19

Certainly. I'd say that figure remains a solid one. The truth is, as you're aware, one must consider what unfolds with these extended premium tax credits. Our framework for thinking about it is this: should they disappear, we'd forfeit that $120 million approximately across a 3-year span, though it wouldn't be distributed evenly. We'd experience something — our projections suggest around $40 million in year 1, $70 million in year 2 and $10 million in year 3. The reason it comes out somewhat lumpy is that our models segment the population. So we operate on the assumption that our current patients, given their strong need for insurance and their grasp of why coverage matters, would be more inclined to keep it. Plus, in numerous instances, it represents the most affordable choice. That calculation shifts once you consider the second group, which consists of patients who don't yet realize their kidneys will fail, so these are CKD patients, and they could allow their insurance to lapse; and if that happens, once their kidneys fail, they'd transition to becoming Medicare patients. Naturally, there's a range within that because certain individuals at CKD 4 are already quite sick. Consequently, they might choose an exchange; so once you work through all those calculations, and as you can observe, it's riddled with assumptions, you arrive at that somewhat lumpy '26, '27 and '28. Beyond that, naturally, we're monitoring Congress since numerous discussions are underway, discussions regarding some form of off ramp, which would mean altering the enhanced tax credits gradually. There's additionally mention of reducing the poverty level to various thresholds. And then, naturally, there are discussions about taking no action. So every one of these assumptions will shift based on whatever transpires.

Joel Ackerman

executive
#20

Regarding what you asked about the private pay mix, Andrew, during this quarter that mix declined by roughly 15 basis points. I'd describe that as typical fluctuation, and compared with the same period a year ago, there's no change.

Albert Rice

analyst
#21

There may be a straightforward explanation here, but it appears your operating income for the quarter came in roughly $50 million under consensus, based on the headline figure. I realize you're stating it matched what you had expected, and the midpoint for the year regarding your outlook hasn't been revised. Is this simply that people modeled it incorrectly because of the day counts you're citing for Q3 and Q4 versus what you were assuming internally? Or, if you have a perspective, what's driving that?

Joel Ackerman

executive
#22

Right; we don't provide quarterly guidance, and we recognize that can create something of a disconnect with the Street. Let me — I believe the clearest way to frame it is through our own thinking, which is that when comparing Q4 against Q3, reaching the midpoint of our guide requires an OI increase of roughly $60 million. And here's how we believe we get there, with all of these figures being approximate: first, seasonal costs typically create a headwind, and we observe that in both patient care costs and G&A. I'd characterize that as a headwind of about $30 million. Three items offset that. The first is volume, which is essentially a day mix matter. Q3 experienced a 60 basis point headwind on day mix year-over-year. Q4 carries a 60 basis point tailwind on day mix, and that contributes roughly $15 million. The second is IKC, which is, let's say, a $25 million increase from Q3 to Q4 in order to meet the IKC guide we provided at the start of the year. And finally, revenue per treatment would be, let's call it, a $50 million pickup. Some seasonality factors into that, from vaccines and standard rate increases. There's also, I'd note, variability beyond what's typical from resolving older claims with payers; these occur nearly every quarter; predicting them is difficult, both regarding size and timing; they, I'd say, tend more often than not to be weighted toward Q4, though not in every year. And for Q4 of '25, we simply anticipate these will be more favorable than is typical.

Albert Rice

analyst
#23

All right. I think that clears things up nicely. Regarding the cyberattack, and the charge you're recording tied to the Mozarc relationship, do those things affect adjusted earnings? For the cyberattack, what would you estimate the specific impact on earnings and volume was during the quarter from that event? Then on the Mozarc charge, it seems there's some — you expect it to be somewhat of a drag for the next year or two, and now that you're taking the charge, does that remove the drag? And does that matter for operating earnings?

Joel Ackerman

executive
#24

Yes. Let me address each of those separately. Starting with Mozarc, the response is that this charge will for the most part remove the Mozarc drag on the P&L in the coming year. It doesn't affect the operating income line; it lands on the other income line. So it isn't part of our adjusted operating income, though it is included in our pretax; and that has been a considerable drag, in both the prior year and this one, and it will come quite near 0 in the coming year; as for cyber, the major effect came in the prior quarter via both RPT and volume. Looking ahead into Q3 and Q4, that effect declines considerably, and it's mostly volume. The cost portion of it has been non-GAAP, in both the prior quarter and this one.

Pito Chickering

analyst
#25

Alright, let me ask one more thing about treatment growth. I know I sound like I keep repeating myself, so my apologies for that. But could you give us details on new patient starts during 3Q and what the year-over-year difference looked like? Also regarding mortality, what's the trend in the third quarter compared with the first half of the year? And last, is there any effect from IOTA on treatment — either on new patient starts or on treatment growth?

Joel Ackerman

executive
#26

Pito, the final portion of what you asked — any impact from what was — I didn't catch that?

Pito Chickering

analyst
#27

That's IOTA, the newly bundled system for kidney transplants.

Joel Ackerman

executive
#28

All right. Yeah. That had no effect. Returning to the first portion of what you asked, I would say quarterly volume landed mostly in line with what we anticipated, though missed treatments put somewhat more pressure on us than we had forecast. Keep in mind, we flagged the missed treatment rate as elevated during Q2 because of the cyberattack. It has fallen from that high point, yet it remains above where it stood in Q3 of 2025. Regarding admissions and mortality, there honestly isn't much fresh to mention. Admissions keeps falling inside the typical range we've observed since COVID. And mortality, once more, is lower compared with Q1, though that mostly reflects flu. There truly isn't any pattern or trend worth noting for mortality, whether we look quarter-over-quarter or year-over-year.

Pito Chickering

analyst
#29

All right, and could you discuss when the IKC funds come in? My understanding is that they usually wrap up at the close of Q3 for the prior calendar year. Has anything shifted regarding when those contracts land? Also, did you already finalize a portion of those funds during October for calendar '24?

Joel Ackerman

executive
#30

Yeah, so the major shift regarding IKC timing this year involved pulling some revenue tied to plan year '24 — money we'd expected in the latter half, with part landing in Q3 — forward into Q2. That explains why IKC performed so well during Q2, and we flagged it as a timing matter. So that's genuinely the main item worth highlighting. Honestly, I expect IKC timing will stay hard to forecast. Much of it depends on when payers and the federal government provide us information, and our capacity to recognize revenue really hinges on that schedule, which is outside our control.

Pito Chickering

analyst
#31

All right. Then here's my final question. The range you're pointing to for Q4 is quite broad — I believe it's around $0.80. For you to land at the bottom versus the top of that range, what would need to occur? And when you consider the midpoint, I know you mentioned treatment growth and a boost from the day mix, but what level of treatment growth ought we to put in our models to reach the midpoint?

Joel Ackerman

executive
#32

Regarding what creates that range, I'd name RPT and IKC as the two items with the greatest potential mix impact there; as for growth in treatment volume, what Q4 should bring is positive volume growth compared with a year earlier. Nothing impressive, 20, 30 bps, roughly in that vicinity, yet still positive — and for the very reason it was so negative during this quarter, namely the day mix acting as a headwind. In the coming quarter, that turns into a tailwind, and that's what will push it positive.

Pito Chickering

analyst
#33

All right, and moving to my final item: when we strip out the cyber incidents, what's your sense of how market share performed in '25?

Joel Ackerman

executive
#34

Yeah. Honestly, that's a genuinely hard one to answer. The strongest source for addressing it would be USRDS data, though the most recent USRDS figures cover Q1 of '25. It was just released for both Q4 of '24 and Q1 of '25. What we've found with that quarterly USRDS information is that we regard the incidence numbers as having greater reliability. The prevalence numbers don't hold up as well. When you factor all of that in, there's essentially no USRDS data available that would let you genuinely attempt to forecast where market share stands.

Javier Rodriguez

executive
#35

Yet when you take that data—flawed though it may be—and combine it with what our people on the ground know, then account for approximately the 1,600 patients affected by both the PD and the cyber outage, nothing suggests we should expect any significant change in market share.

Justin Lake

analyst
#36

Joel, that seems like it should represent roughly a $10 improvement from one quarter to the next. Do I have that about right?

Joel Ackerman

executive
#37

My estimate would be closer to $8.

Justin Lake

analyst
#38

All right. And what portion of that would you consider to be this collection, which we might view as potentially non-recurring at a similar scale?

Joel Ackerman

executive
#39

I'd say — it is — I mentioned $50 million of RPT improvement, and that equals roughly $7 of RPT. That represents the largest piece of it. So I'd rather not provide a precise figure there. This involves ranges within ranges, but I would say more than half is likely a fair estimate.

Justin Lake

analyst
#40

Great. Then regarding the assumption for volume in Q4, I’m sorry if I didn’t catch it, but did you provide a figure for what you expect on volume?

Joel Ackerman

executive
#41

See, you can more or less derive it. As for treatment volume, growth would be approximately 20 or 30 bps. And keep in mind, that is treatment volume, not treatments per day, and not NAG; that would be roughly 20 or 30 bps of absolute year-over-year growth.

Ryan Langston

analyst
#42

You brought up shifts in payer mix that pushed RPT lower somewhat. Could you share the commercial treatment mix for the quarter, or at minimum the proportion — or how it moved versus the second quarter? And Joel, I caught your comments on the sequential pieces within RPT, and I appreciate that, but when it comes to the 4Q guide, is any kind of favorable shift in that payer mix baked in?

Joel Ackerman

executive
#43

My sense is it won't play a big role in that. As for the mix's current level, it sits at approximately 11%. It had declined 11% — excuse me, between Q2 and Q3 it fell 15 bps. It moved from slightly above 11% to slightly below 11%.

Ryan Langston

analyst
#44

All right. And the final item, I suppose, across the last 1 or 2 years, we have observed solid expansion in RPT, the binders obviously, but let's concentrate on the gains in the revenue cycle. I suppose, where do we stand within the life cycle of those, or at minimum are we seeing a few outsized advantages from them? Javier, I caught you referencing a few initiatives during your prepared remarks. But anything at all regarding revenue cycle initiatives and gains would be useful.

Joel Ackerman

executive
#45

Yeah. I would say a few folks would inquire which inning of the game we are in. I believe that is an incorrect metaphor. This is an ongoing process that I do not believe we — sort of we complete it and then we proceed onward. I believe there is — there will be an ongoing process for years and years to keep getting better at it. Keep in mind, a 1% gain in ROPS collections equals roughly $120 million of OI. So even if we are able to just achieve 10 or 20 basis points year in, year out, there is genuine value in that. The cyber incident certainly decelerated things there, and — yet we are persisting in investing there. As Javier stated, AI represents an opportunity, plain old-fashioned automation represents an opportunity there too; so I would say we are not — there is more to be gained there; it will not feel the way it did in '23 and '24, when it was truly shifting the needle in a major way, but I think there will be — keep being opportunity there year in and year out.

Javier Rodriguez

executive
#46

Alright. Michelle, thank you, and I appreciate every one of your questions. To close things out, I'd like to share 4 final points. To begin, we ran into 2 unforeseen hurdles early in the year that carried a significant financial toll; we worked our way through them, provided outstanding clinical care to our patients, and we're still positioned to hit the guidance we set for the year. At the same time, we keep putting money into building capabilities for the long haul. Next, our approach to deploying capital will stay disciplined, and that includes buying back shares. Third, we shared some perspective looking ahead toward next year. While the conversation right now centers on enhanced premium tax credits, on a wider level we'll be watching open enrollment, which may be the largest variable as we head into 2026. Last of all, the clinical and operational work supporting middle molecule clearance will need roughly 3 years before results appear, but the chance to improve patients' lives is significant and thrilling. Thanks to everyone for being on the call, and take care.

Operator

operator
#47

Thanks. That brings us to the end of today's conference call. At this point, you're welcome to disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.